A Post-market Registry of the MARIS-stent (Invatec) Implanted in the Superficial Femoral Artery

Recent data suggest that there is some evidence for a reduced restenosis rate for the implantation of a self expanding nitinol stent in the superficial femoral artery (SFA) compared to implantation of balloon expandable stents or single balloon inflation (ABSOLUTE study/FAST study).

The purpose of the Maris Register is to evaluate the primary nitinol stent implantation in an all comer population with diseased SFA.

The MARIS Register is a prospective, multicenter registry of the implantation of at least one at most five nitinol stents (Maris / Invatec) in the SFA without limitations for stenosis or occlusion length.

The registry includes 998 patients from 13 German investigational sites. Clinical data are captured on electronic case report forms

The primary endpoint is the target lesion revascularization after 12 month

Secondary endpoints are :

• Restenosis rate > 50% according to ultrasound criteria
• Restenosis rate > 70% according to ultrasound criteria
• Location of restenosis (proximal, middle, distal AFS)
• Number of stent fractures (grading according to FESTO criteria)
• Procedure related complication rate
• Vascular complication rate within 12 month
• Amputations within 12 month
• Deaths within 12 month

In order to measure the restenosis the peak systolic velocity (PSV) is to be measured in two sections during the duplex ultrasound examinations at 6 and 12 month. First measurement is performed 2cm proximal to the first stent, second measurement at the location where the maximum peak velocity over all lesions/all implanted stents is measured.

The clinical status includes the patient´s Fontaine classification.

Inclusion criteria

• stent implantation in SFA is possible
• existing SFA stenosis 70-100 % (visual estimation)
• absence of homodynamically relevant stenosis in A. poplitea
• at least one lower limb run off vessel

Exclusion criteria

• pregnancy
• life expectancy less than 1 year
• coagulation disorder
• chronic anticoagulation therapy
• active gastrointestinal bleeding
• thrombolytic therapy within 72 hours before intervention
• hyperthyreosis
• severe contrast agent allergy
• allergy to concomittant medication
• severe liver disease
• thrombus in target lesion
• target lesion extend into A. poplitea
• severe calcification of target vessel, where no successful pre-dilatation is feasible